RANITIDINE CONTROLLED RELEASE ANTI-REFLUX SUSPENSION FOR GASTRO-OESOPHAGEAL REFLUX DISEASE AND IT’S IN VITRO EVALUATION

  • Sangmesh R. Torne India Innovation Center, DuPont Nutrition and Health (Formerly FMC Health and Nutrition), Bangalore, India
  • Sheela A. Department of Chemistry, School of Advanced sciences, Vellore Institute of Technology, Vellore, Tamil Nadu, India
  • Sarada N. C. Department of Chemistry, School of Advanced sciences, Vellore Institute of Technology, Vellore, Tamil Nadu, India

Abstract

Objective: The aim of this work was to develop triple action controlled release anti-reflux suspension of ranitidine and its in-vitro evaluation of anti-reflux and controlled release properties.


Methods: The formulation was optimized using sodium alginate as a gelling agent along with calcium carbonate, sodium bicarbonate, magnesium hydroxide, aluminium hydroxide as alkalizing agents and colloidal microcrystalline cellulose (MCC) as a suspending agent at various concentrations and arrived at an optimized formulation for its best quality attributes. To avoid initial release in water before administration, ranitidine coated MCC sphere was incorporated into powder formulation and subjected to in vitro characteristics like raft strength, acid neutralizing capacity, pH, viscosity and dissolution study. The obtained results were assessed using Minitab 17 statistical software to conclude the study design.


Results: Formulation containing 300 mg of ranitidine along with 750 mg alginate has shown better anti-reflux characteristics like raft strength 18±2g, acid neutralizing capacity 17±1 mEq compared to other formulations. This formulation has also shows zero-order controlled release in the simulated gastric fluid (SGF) up to 10 h compared to the formulation without alginate. Further, to this optimized formulation has shown negligible change in the assay of ranitidine even after 3 mo at 40 °C temperature and 75% RH.


Conclusion: The developed stable sustained release powder for suspension has the combined therapeutic efficacy as an antacid and anti-reflux drug suitable for the management and treatment of gastro-oesophageal reflux disease (GERD) unlike the existing drugs possessing only reflux resistance action.

Keywords: Suspension, Alginate, Gastro-oesophageal reflux disease, Raft, Controlled release, Ranitidine
Statistics
106 Views | 111 Downloads
How to Cite
Torne, S. R., A., S., & C., S. N. (2019). RANITIDINE CONTROLLED RELEASE ANTI-REFLUX SUSPENSION FOR GASTRO-OESOPHAGEAL REFLUX DISEASE AND IT’S IN VITRO EVALUATION. International Journal of Applied Pharmaceutics, 11(1), 74-81. https://doi.org/10.22159/ijap.2019v11i1.28754
Section
Original Article(s)